Abstract

In the U.S., Neisseria meningitidis serogroup B (MenB) is responsible for about half of all cases of invasive meningococcal disease in people aged 17 to 22. Recently, two MenB vaccines were licensed for use in this country. On February 2, 2015, a case of MenB disease was reported in a male student attending Providence College. Three days later, …

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.